TP53 and neoplasm: The above-mentioned large-scale integrated genomic characterization of 150 PDAC cases by TCGA Research Network found KRAS to be mutated in 93%, TP53 in 72%, SMAD4 in 32% and CDKN2A in 30% of PC tumor tissue samples [26].